alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Fusions'],"[{'ncitCode': 'C121553', 'drugName': 'Pemigatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['32203698'],[],"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698)."
['Fusions'],"[{'ncitCode': 'C114283', 'drugName': 'Futibatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],"['34551969', '36652354']",[],"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273)."
['Fusions'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37541273'],[],"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}",[],['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C103273', 'drugName': 'Erdafitinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
['Oncogenic Mutations'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}, {'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}]",['37270847'],"[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847)."
['Oncogenic Mutations'],"[{'ncitCode': 'C88272', 'drugName': 'Fexagratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}","[{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}]","['31088831', '32463741']",[],"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831)."
